Ordastobart
Based on 1 Customer Validation
Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98%
- No. CAS: 2708115-83-5
- Peso molecular:128.96 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Ver todos los productos específicos de isoformas Orexin Receptor (OX Receptor)
More
Actividad biológica
[G1 VH-VH-VH-h-CH2-CH3]-dimer
Human
TNFRSF4/OX40/CD134
Ordastobart (5-25 nM, 1 h at 37°C) induces high clustering of the OX40 receptor in CHO cells expressing a human OX40 extracellular domain coupled to GFP[1].
Ordastobart (0.001-1000 nM, 96 h) stimulates CD4+ and CD8+ cells enriched from PBMC[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CHO cells expressing a human OX40 extracellular domain coupled to GFP
-
Concentration:5, 25 nM
-
Incubation Time:1 h at 37°C
-
Result:Enhanced high-level co-occurrence of GFP (green) and AF647 (magenta) on the cell membrane.
-
Cell Line:CD4+ and CD8+ T cells enriched from healthy donor peripheral blood mononuclear cells (PBMC)
-
Concentration:0.001, 0.01, 0.1, 1, 10, 100, 1000 nM
-
Incubation Time:96 h at 37°C
-
Result:Increaseed human leukocyte antigen (HLA)-DR expression, with maximum activity reaching a peak between 0.1-10 nM and declining at concentrations above 10 nM.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCA-205 (C57BL/6) or CT26 (BALB/c) tumor-bearing (106) mice (6-8 weeks old, female) model[1]
-
Dosage:10 µg/single dose
-
Administration:i.v.
-
Result:Demonstrated good tolerability, reduced tumor size, and significantly improved survival.
Engaged and activated CD8+ T cells to control tumor growth.
Expanded CD8+ T cells within tumors and increases T cell frequency and proliferation within LNs; reduces CD8+ T cell frequency in tdLNs but increases proliferation Ki-67.
Increased CD4+ Teff proliferation as compared with controls, enhanced interferon (IFN)-γ and TNF-α production.
Increased the frequency of CD8+ T cells and decreased the frequency of Tregs compared with controls.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
VH-VH-VH-h-CH2-CH3
ELISA, FACS, Functional assay
-
Loaded Ordastobart on ProA biosensor, can bind OX40/TNFRSF4 Protein, Human (Biotinylated, HEK293, His-Avi, HY-P78189) with an affinity constant of 1.30E-10 M as determined in BLI assay.
Chemical Information
-
No. CAS 2708115-83-5
-
Appearance Liquid
-
Peso molecular 128.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Ordastobart]
-
Synonyms
INBRX-106; ES-102
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)